Phase 2 studies of two novel treatments for primary biliary cholangitis report encouraging results

(European Association for the Study of the Liver) Ongoing Phase 2 studies of tropifexor and seladelpar report promising preliminary efficacy, safety and tolerability results, paving the way for longer-term studies in patients with primary biliary cholangitis